When prolonged thrombocytopenia occurring in the setting of CAR-T therapy persists beyond day 30, we recommend to double check that nutritional parameters are replete, and we also recommend a TPO mimetic drug such as eltrombopag or romiplostim in those with a substantial risk of bleeding (platelets <10,000/μL) to mitigate the risk of severe hemorrhage. Here, TPO is linked to Thrombocytopenia.